Mechanobiology of Progenitor Cells in Heterotopic Ossification

异位骨化中祖细胞的力学生物学

基本信息

  • 批准号:
    9926811
  • 负责人:
  • 金额:
    $ 33.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Abstract Although rare genetic disorders directly impact relatively small segments of the population, they are caused by mutations in genes with such critical importance that perturbed function is rarely tolerated, and therefore offer unique insight into fundamental cellular mechanisms. One such disease, fibrodysplasia ossificans progressiva (FOP), is caused by misregulated control of cell fate decisions that leads to congenital skeletal malformations and disabling extra-skeletal (heterotopic) endochondral ossification (HO) that often forms in response to tissue injury. Notably, this de novo bone formation is associated with an impaired muscle repair response. We identified that all familial and sporadic cases with classic features of FOP carry the same heterozygous mutation in ACVR1/ALK2 (R206H; c.617G>A), a cell surface receptor that mediates signal transduction of bone morphogenetic proteins (BMPs). Our data showed that the ACVR1 R206H mutant receptors mildly activate the BMP signaling pathway in the presence or absence of BMP ligands. This proposal seeks to identify how the resulting gain of function in ACVR1/BMP signaling diverts the program of muscle repair from one that normally culminates in restoration of muscle tissue to one in which muscle injury leads to differentiation of endogenous mesenchymal progenitor cells (MSCs) to chondrocytes and osteoblasts and the formation of heterotopic bone tissue. Previous studies confirmed cell autonomous effects of the mutation on MSC differentiation, however, while the mutation enhances MSC chondro/osteogenesis, we have also established that mutant cells do not spontaneously differentiate, but require additional signals. Since commitment and differentiation of tissue-resident progenitor cells is regulated by signals from the tissue microenvironment, and the tissue microenvironment is itself defined by matrix production by these differentiating cells, this proposal focuses on how enhanced BMP pathway signaling in FOP changes cellular interpretation and fabrication of the biomechanical environment during muscle repair. Based on our preliminary data showing altered physical (mechanical) properties of mutant skeletal muscle tissue following injury, this proposal will first investigate and identify the mechanisms (cellularity, matrix, and stiffness) through which ACVR1 R206H mutant tissue alters the connective tissue microenvironment during the early response to muscle injury (Aim 1). Next, we will examine the mechano-sensing signaling mechanisms through which chondro/osseous mesenchymal (non-myogenic) progenitor cells (MSCs) differentially sense and interpret signals from their microenvironment (Aim 2). Finally, we will determine the effects of the mutant tissue microenvironment on endogenous myogenic muscle progenitor cells (MuSCs, Aim 3). Together, these data will identify novel mechano-regulatory mechanisms controlling cell differentiation in heterotopic ossification and muscle repair and as well as reveal new targets for therapeutic interventions to prevent genetic and non- genetic forms of HO and to engineer tissues for clinical application.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert L Mauck其他文献

Robert L Mauck的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert L Mauck', 18)}}的其他基金

Training Program in Musculoskeletal Research
肌肉骨骼研究培训计划
  • 批准号:
    10861378
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
Activation of endogenous progenitors via a nanoparticle-conjugated fibrous system to enhance meniscus repair
通过纳米颗粒共轭纤维系统激活内源祖细胞以增强半月板修复
  • 批准号:
    10607306
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
Knee Joint Resurfacing with Anatomic Tissue Engineered Osteochondral Implants
使用解剖组织工程骨软骨植入物进行膝关节表面置换
  • 批准号:
    10704534
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
RR&D Research Career Scientist Award Application
RR
  • 批准号:
    10533303
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
Knee Joint Resurfacing with Anatomic Tissue Engineered Osteochondral Implants
使用解剖组织工程骨软骨植入物进行膝关节表面置换
  • 批准号:
    10248368
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
Hydrogel Delivery of Extracellular Vesicles to Treat Osteoarthritis
水凝胶递送细胞外囊泡治疗骨关节炎
  • 批准号:
    10631851
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
RR&D Research Career Scientist Award Application
RR
  • 批准号:
    10311108
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
Hydrogel Delivery of Extracellular Vesicles to Treat Osteoarthritis
水凝胶递送细胞外囊泡治疗骨关节炎
  • 批准号:
    10176189
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
Knee Joint Resurfacing with Anatomic Tissue Engineered Osteochondral Implants
使用解剖组织工程骨软骨植入物进行膝关节表面置换
  • 批准号:
    10454898
  • 财政年份:
    2020
  • 资助金额:
    $ 33.91万
  • 项目类别:
Mechanobiology of Progenitor Cells in Heterotopic Ossification
异位骨化中祖细胞的力学生物学
  • 批准号:
    10401824
  • 财政年份:
    2018
  • 资助金额:
    $ 33.91万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 33.91万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 33.91万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了